About Wei-Hsuan "Jenny" Lo-Ciganic
Wei-Hsuan “Jenny” Lo-Ciganic, M.S.Pharm, M.S., Ph.D. joined the University of Florida College of Pharmacy, department of pharmaceutical outcomes and policy as an assistant professor in 2018. She is a pharmacoepidemiologist, with research interests in drug safety, medication adherence, prescription drug abuse and quality and value of prescribing, especially among vulnerable or minority populations. Her interests in patient safety and quality of care issues focus on improving and developing quality measures and prediction tools using advanced analytics (e.g., machine learning).
Prior to arriving at the University of Florida, Lo-Ciganic worked as an assistant professor at the University of Arizona College of Pharmacy from 2015-18. She was a recipient of the 2015 University of Arizona Health Science Career Development Award and 2016 American Association of Colleges of Pharmacy New Investigator Award. In 2017, Lo-Ciganic received the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Research Starter Award in Health Outcomes. Recently she became the Co-PI for the R01 project, “Using Machine Learning to Predict Problematic Opioid Use”, in two large state Medicaid programs, which has been funded by the National Institute of Drug Abuse (NIDA). Since 2015, she has been a member and co-chair of the Pharmacy Quality Alliance’s (PQA) workgroups and Quality Metrics Expert Panel to develop and improve quality measures of prescription medications.
Honors & Awards
The UF Excellence Award for Assistant Professors is one of the university’s top awards for a junior faculty member.
The virtual workshop will address how machine learning and data mining techniques can enhance health economics outcomes research.
The study was published in JAMA Open Network and its findings may be valuable for clinical decision-making regarding treatment regimen selection for individuals with advanced melanoma.
Lo-Ciganic’s research team will develop a real-time trajectory tool to identify potentially unsafe concurrent opioid and benzodiazepine use among older adults.